Abstract
Modification of the terminal tails of histones is considered one of the documented mechanisms for epigenetic control of gene expression. Histone deacetylase inhibitors (HDACi) lead to a state of hyperacetylation of histone, a condition that can affect normal gene transcription. Furthermore, HDACi have many other protein targets involved in regulation of gene expression, cell proliferation and cell death. For these properties some HDACi are nowadays used as anticancer drugs with promising results. Several molecules with HDACi properties (valproic acid, trichostatin A, apicidin, MS-275, sodium butyrate, boric acid, salicylic acid) have been found to induce congenital malformations associated with hyperacetylation of histones in the target organs. Cell death is the major event in the target organs a few hours after embryonic exposure to HDACi. Gene deregulation, oxidative stress, DNA demethylation, and/or retinoic acid imbalance are the modes of action postulated for HDACi-induced teratogenesis.
Keywords: HDAC inhibitors, teratogenesis, congenital malformations, mechanisms.
Current Pharmaceutical Design
Title:Teratogenic Activity of HDAC Inhibitors
Volume: 20 Issue: 34
Author(s): Erminio Giavini and Elena Menegola
Affiliation:
Keywords: HDAC inhibitors, teratogenesis, congenital malformations, mechanisms.
Abstract: Modification of the terminal tails of histones is considered one of the documented mechanisms for epigenetic control of gene expression. Histone deacetylase inhibitors (HDACi) lead to a state of hyperacetylation of histone, a condition that can affect normal gene transcription. Furthermore, HDACi have many other protein targets involved in regulation of gene expression, cell proliferation and cell death. For these properties some HDACi are nowadays used as anticancer drugs with promising results. Several molecules with HDACi properties (valproic acid, trichostatin A, apicidin, MS-275, sodium butyrate, boric acid, salicylic acid) have been found to induce congenital malformations associated with hyperacetylation of histones in the target organs. Cell death is the major event in the target organs a few hours after embryonic exposure to HDACi. Gene deregulation, oxidative stress, DNA demethylation, and/or retinoic acid imbalance are the modes of action postulated for HDACi-induced teratogenesis.
Export Options
About this article
Cite this article as:
Giavini Erminio and Menegola Elena, Teratogenic Activity of HDAC Inhibitors, Current Pharmaceutical Design 2014; 20 (34) . https://dx.doi.org/10.2174/1381612820666140205144900
DOI https://dx.doi.org/10.2174/1381612820666140205144900 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Risk of Drug Resistance and Repeated Infection with <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in Intensive Care Unit Cancer Patients
Combinatorial Chemistry & High Throughput Screening Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Current Pediatric Reviews Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Editorial [Hot topic: Infectious Diseases and Hematology: At the Crossroad of Contemporary Therapy (Guest Editors: Hau C. Kwaan and Michael G. Ison)]
Infectious Disorders - Drug Targets The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Antifungal Drug Discovery, Six New Molecules Patented After 10 Years of Feast:Why do we Need New Patented Drugs Apart from New Strategies?
Recent Patents on Anti-Infective Drug Discovery Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Reviews on Recent Clinical Trials Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry